 |
0 Diseases |  |
28 Trials |
|
28 Trials |  |
211 News |  |
| «12345» |
- | Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: BeTRI: Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 19, 2017
P2, N=45, Active, not recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Recruiting --> Active, not recruiting
- |||||||||| Vectibix (panitumumab) / Amgen
New P3 trial, Metastases: 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab (clinicaltrials.gov) - Oct 3, 2017
P3, N=450, Not yet recruiting, Sponsor: University of Southern California
- |||| Vectibix (panitumumab) / Amgen
Trial completion, Combination therapy, Metastases: SAPPHIRE: Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-na (clinicaltrials.gov) - Sep 11, 2017
P2, N=164, Completed, Sponsor: Takeda
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | leucovorin calcium / Generic mfg.
Trial initiation date, Trial primary completion date: Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder (clinicaltrials.gov) - Sep 11, 2017
P3, N=160, Not yet recruiting, Sponsor: Emory University
Active, not recruiting --> Completed Initiation date: Nov 2016 --> Nov 2017 | Trial primary completion date: Jan 2021 --> Jan 2022
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: ATOM: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Aug 2, 2017
P2, N=122, Completed, Sponsor: EPS Corporation
Initiation date: Nov 2016 --> Nov 2017 | Trial primary completion date: Jan 2021 --> Jan 2022 Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial completion: ATOM ES: Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Aug 2, 2017
P=N/A, N=110, Completed, Sponsor: EPS Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P2 trial, Combination therapy, Metastases: Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC (clinicaltrials.gov) - Jul 19, 2017
P2, N=60, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- ||||| Vectibix (panitumumab) / Amgen
Enrollment closed, Combination therapy, Metastases: PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) - Jun 16, 2017
P3, N=823, Active, not recruiting, Sponsor: Takeda
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Vectibix (panitumumab) / Amgen
Biomarker, Enrollment closed, Metastases: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-na (clinicaltrials.gov) - Jun 16, 2017
P3, N=766, Active, not recruiting, Sponsor: Takeda
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Vectibix (panitumumab) / Amgen
Biomarker, Trial primary completion date, Metastases: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-na (clinicaltrials.gov) - Jun 8, 2017
P3, N=800, Recruiting, Sponsor: Takeda
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2017 --> Feb 2020
- ||| Vectibix (panitumumab) / Amgen
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: SAPPHIRE: Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-na (clinicaltrials.gov) - Apr 11, 2017
P2, N=164, Active, not recruiting, Sponsor: Takeda
Trial primary completion date: Apr 2017 --> Feb 2020 Recruiting --> Active, not recruiting | N=100 --> 164 | Trial primary completion date: Aug 2017 --> Mar 2017
- |||| Vectibix (panitumumab) / Amgen
Biomarker, Trial primary completion date, Metastases: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-na (clinicaltrials.gov) - Apr 10, 2017
P3, N=800, Recruiting, Sponsor: Takeda
Recruiting --> Active, not recruiting | N=100 --> 164 | Trial primary completion date: Aug 2017 --> Mar 2017 Trial primary completion date: Sep 2018 --> Apr 2017
- ||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Enrollment closed, Combination therapy, Metastases: Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer (clinicaltrials.gov) - Apr 6, 2017
P2, N=80, Active, not recruiting, Sponsor: Baxalta US Inc.
Trial primary completion date: Sep 2018 --> Apr 2017 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, napabucasin (BBI608) / Sumitomo Pharma
Trial completion, Metastases: A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 23, 2017
P1, N=4, Completed, Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed
- 5-fluorouracil / Generic mfg., paclitaxel / Generic mfg., irinotecan / Generic mfg.
New trial, Metastases: mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA (clinicaltrials.gov) - Feb 7, 2017
P=N/A, N=150, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- || Vectibix (panitumumab) / Amgen
Trial primary completion date, Combination therapy, Metastases: SAPPHIRE: Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-na (clinicaltrials.gov) - Dec 7, 2016
P2, N=100, Recruiting, Sponsor: Takeda
Recruiting --> Completed Trial primary completion date: Sep 2016 --> Aug 2017
- || leucovorin calcium / Generic mfg.
New P3 trial: Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder (clinicaltrials.gov) - Jul 23, 2016
P3, N=160, Not yet recruiting, Sponsor: Emory University
- Avastin (bevacizumab) / Roche
Metastases: BeTRI: Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 19, 2016
P2, N=45, Recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Trial primary completion date: Sep 2016 --> Aug 2017 Trial primary completion date: Mar 2016 --> Sep 2018
- |||||| Enrollment open: Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer (clinicaltrials.gov) - Jun 24, 2016
P3, N=230, Recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
Trial primary completion date: Mar 2016 --> Sep 2018 Not yet recruiting --> Recruiting
- |||||||||| New P3 trial: Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer (clinicaltrials.gov) - May 27, 2016
P3, N=230, Not yet recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
- |||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Enrollment open, Combination therapy, Metastases: Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer (clinicaltrials.gov) - Apr 6, 2016
P2, N=80, Recruiting, Sponsor: Baxalta US Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: ATOM: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Mar 29, 2016
P2, N=120, Active, not recruiting, Sponsor: EPS Corporation
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment closed: ATOM ES: Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Mar 29, 2016
P=N/A, N=100, Active, not recruiting, Sponsor: EPS Corporation
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
New P2 trial, Combination therapy, Metastases: Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer (clinicaltrials.gov) - Mar 4, 2016
P2, N=80, Not yet recruiting, Sponsor: Baxalta US Inc.
- | tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial completion, Trial primary completion date, Combination therapy, Metastases: Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach (clinicaltrials.gov) - Jan 19, 2016
P1/2, N=47, Completed, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jul 2015
- Avastin (bevacizumab) / Roche, napabucasin (BBI608) / Sumitomo Pharma
New P1 trial, Metastases: A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 30, 2015
P1, N=6, Recruiting, Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
- SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial primary completion date: Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer (clinicaltrials.gov) - Dec 10, 2015
P3, N=162, Recruiting, Sponsor: Universiteit Antwerpen
Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jul 2015 Trial primary completion date: Aug 2016 --> Dec 2017
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: DEEPER: A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab (clinicaltrials.gov) - Aug 5, 2015
P2, N=360, Not yet recruiting, Sponsor: Japan Clinical Cancer Research Organization
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: BeTRI: Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 14, 2015
P2, N=45, Recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
- |||||| Vectibix (panitumumab) / Amgen
Enrollment open, Combination therapy, Metastases: PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) - Jun 10, 2015
P3, N=800, Recruiting, Sponsor: Takeda
Trial primary completion date: Aug 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- |||||| Vectibix (panitumumab) / Amgen
Biomarker, Enrollment open, Metastases: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-na (clinicaltrials.gov) - Jun 9, 2015
P3, N=800, Recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Vectibix (panitumumab) / Amgen
New P3 trial, Combination therapy, Metastases: PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) - Mar 20, 2015
P3, N=800, Not yet recruiting, Sponsor: Takeda
- |||||||||| Vectibix (panitumumab) / Amgen
Biomarker, New P3 trial, Metastases: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-na (clinicaltrials.gov) - Mar 20, 2015
P3, N=800, Not yet recruiting, Sponsor: Takeda
- ||||| Vectibix (panitumumab) / Amgen
New P2 trial, Combination therapy, Metastases: SAPPHIRE: Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-na (clinicaltrials.gov) - Jan 15, 2015
P2, N=100, Recruiting, Sponsor: Takeda
- | SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial initiation date: Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer (clinicaltrials.gov) - Apr 24, 2014
P3, N=162, Recruiting, Sponsor: Universiteit Antwerpen
Not yet recruiting --> Recruiting Initiation date: Jun 2013 --> Aug 2013
- | SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Enrollment open: Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer (clinicaltrials.gov) - Apr 24, 2014
P3, N=162, Recruiting, Sponsor: Universiteit Antwerpen
Initiation date: Jun 2013 --> Aug 2013 Active, not recruiting --> Recruiting
- | tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Enrollment closed, Combination therapy, Metastases: Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach (clinicaltrials.gov) - Mar 16, 2014
P1/2, N=50, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Modufolin (arfolitixorin) / Isofol Medical, Solasia
Enrollment change: PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer (clinicaltrials.gov) - Oct 13, 2013
P1/2, N=32, Completed, Sponsor: Isofol Medical AB
Recruiting --> Active, not recruiting N=64 --> 32
- | Modufolin (arfolitixorin) / Isofol Medical, Solasia
Trial completion: PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer (clinicaltrials.gov) - Oct 13, 2013
P1/2, N=32, Completed, Sponsor: Isofol Medical AB
N=64 --> 32 Recruiting --> Completed
- Folotyn (pralatrexate) / Aurobindo
Trial withdrawal: Phase 1 Study of Fusilev (clinicaltrials.gov) - Sep 2, 2013
P1, N=0, Withdrawn, Sponsor: Spectrum Pharmaceuticals, Inc
Recruiting --> Completed Not yet recruiting --> Withdrawn
- Folotyn (pralatrexate) / Aurobindo
Enrollment change: Phase 1 Study of Fusilev (clinicaltrials.gov) - Sep 2, 2013
P1, N=0, Withdrawn, Sponsor: Spectrum Pharmaceuticals, Inc
Not yet recruiting --> Withdrawn N=75 --> 0
- Folotyn (pralatrexate) / Aurobindo
Trial withdrawal: Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn (clinicaltrials.gov) - Jul 22, 2013
P1, N=0, Withdrawn, Sponsor: Spectrum Pharmaceuticals, Inc
N=75 --> 0 Not yet recruiting --> Withdrawn
- Folotyn (pralatrexate) / Aurobindo
Enrollment change: Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn (clinicaltrials.gov) - Jul 22, 2013
P1, N=0, Withdrawn, Sponsor: Spectrum Pharmaceuticals, Inc
Not yet recruiting --> Withdrawn N=75 --> 0
- || SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
New P3 trial: Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer (clinicaltrials.gov) - Jul 8, 2013
P3, N=162, Recruiting, Sponsor: Universiteit Antwerpen
- |||| oxaliplatin / Generic mfg., sorafenib / Generic mfg.
Trial completion, Combination therapy, Metastases: Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects (clinicaltrials.gov) - May 6, 2013
P2, N=198, Completed, Sponsor: Bayer
N=75 --> 0 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: ATOM: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - May 5, 2013
P2, N=180, Recruiting, Sponsor: EPS Corporation
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment open: ATOM ES: Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - May 5, 2013
P=N/A, N=100, Recruiting, Sponsor: EPS Corporation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: ATOM: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Apr 18, 2013
P2, N=180, Recruiting, Sponsor: EPS Corporation
- Folotyn (pralatrexate) / Aurobindo
New P1 trial: Phase 1 Study of Fusilev (clinicaltrials.gov) - Mar 26, 2013
P1, N=0, Withdrawn, Sponsor: Spectrum Pharmaceuticals, Inc
- Folotyn (pralatrexate) / Aurobindo
New P1 trial: Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn (clinicaltrials.gov) - Feb 10, 2013
P1, N=0, Withdrawn, Sponsor: Spectrum Pharmaceuticals, Inc